Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | N/A | -7.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.56 | N/A | -7.28% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the financial outlook. They emphasized their commitment to ongoing clinical development without offering specific guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its clinical programs despite the current challenges.
Crinetics Pharmaceuticals reported a loss that was slightly worse than expected, leading to a 6.01% drop in stock price. The lack of revenue figures and guidance may have contributed to investor uncertainty. The company's focus on clinical programs suggests they are prioritizing long-term growth over short-term financial performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
JOHNSON CONTROLS INT
Nov 3, 2020